INTRODUCTION {#s1}
============

Pancreatic neuroendocrine neoplasms (PanNENs) are neoplasms of the endocrine pancreas. These tumors account for 3%--5% of all pancreatic malignancies and in general have a better prognosis than typical pancreatic exocrine malignancies. Positive outcomes are largely dependent on complete surgical excision, as 5-yr survival approaches 55% when tumors are localized and resected, in contrast to 15% when they are not resectable ([@MCS003814WILC13]; [@MCS003814WILC11]). Although PanNENs can closely approximate the morphology of neuroendocrine tumors of the gastrointestinal tract, their biologies differ, and it is, therefore, clinically advantageous to investigate alternative diagnostic and treatment approaches ([@MCS003814WILC25]).

PanNEN classification uses tumor morphology and grade to partition well-differentiated from poorly differentiated entities ([@MCS003814WILC24]). Poorly differentiated pancreatic neuroendocrine carcinomas (PanNEC) are characterized by both a high mitotic count (\>20 per 10 high power field) and a high proliferation index (Ki-67 \> 20%). Well-differentiated pancreatic neuroendocrine tumors (PanNETs) tend to have lower mitotic rates and proliferation indices, classified into low-grade (G1) or intermediate-grade (G2) on the basis of their Ki-67 staining profiles (\<3% and between 3% and 20% of tumor cells, respectively). It is also now recognized that a less-common subset of morphologically well-differentiated PanNETs has an incongruously high proliferation index (Ki-67 \> 20%). Despite their high proliferative rate, these tumors appear to be separate biologic entities from the poorly differentiated NECs, so are now classified as high-grade (G3) PanNETs ([@MCS003814WILC8]; [@MCS003814WILC44]; [@MCS003814WILC30]).

Recurring molecular aberrations in PanNETs have been described in studies using whole-exome and whole-genome sequencing. Namely, mutations in *DAXX* and *ATRX* (chromatin remodeling genes) and *TSC2*, *PTEN*, *PIK3CA*, and *MEN1* (mTOR pathway genes) have been observed ([@MCS003814WILC20]; [@MCS003814WILC39]; [@MCS003814WILC45]). Moreover, individuals exhibiting germline mutations in *TSC1/2* (tuberous sclerosis), *MEN1* (multiple endocrine neoplasia 1), *VHL* (von Hippel--Lindau), and *NF1* (neurofibromatosis type 1) are at increased risk of developing PanNETs ([@MCS003814WILC19]).

[@MCS003814WILC39] provide a large-scale whole-genome landscape of PanNETs, which included five G3 PanNETs in their analysis, but the literature to date has an otherwise limited characterization of molecular aberrancy in these tumors. To this end, this report represents a complete genomic and transcriptomic characterization of a patient with a metastatic well-differentiated G3 PanNET.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A previously healthy 35-yr-old male presented with weight loss and pain. Imaging demonstrated a mass in the pancreatic tail and liver metastasis. The patient was referred to the Personalized OncoGenomics Program (POG) for whole-genome and transcriptome analysis (NCT02155621) ([@MCS003814WILC27]). A core needle biopsy of one of the liver lesions revealed a G3 well-differentiated neuroendocrine tumor (Ki-67 = 30%; chromogranin- and CK7-positive; CK20-negative; octreotide scan--negative) ([Fig. 1](#MCS003814WILF1){ref-type="fig"}).

![Tumor histopathology and Ki-67 immunohistochemistry. (*A*) Core biopsy of a liver metastasis stained for hematoxylin and eosin showing a metastatic well-differentiated neuroendocrine tumor clinicoradiologically consistent with pancreatic origin (magnification at 10× \[*left*\] and 40× \[*right*\]). (*B*) Paired Ki-67 immunohistochemistry showing a proliferative index of 30%, classifying the tumor as a well-differentiated grade 3 (G3) neuroendocrine tumor (magnification at 10× \[*left*\] and 40× \[*right*\]).](MCS003814Wil_F1){#MCS003814WILF1}

Genomic Analysis {#s2b}
----------------

Whole-genome sequencing of liver metastases and blood was performed for comparative analysis and detection of somatic single-nucleotide variants (SNVs), insertion and deletions (indels), structural variants, and copy-number variants. RNA sequencing was performed to support variants detected by genomic sequencing and identify altered gene expression. Tumor content, as based on the tumor/normal sequencing ratio and loss of heterozygosity, was estimated to be 95% and a diploid model was used to describe the observed copy-number changes.

### Single-Nucleotide Variants {#s2b1}

Comparative analysis of whole-genome sequencing from tumor and normal samples revealed 4232 somatic SNVs. Somatic SNVs were compared to a catalog of previously described mutation signatures (<http://cancer.sanger.ac.uk/cosmic/signatures>) using the signIT package (<https://github.com/eyzhao/SignIT/>; EY Zhao, E Pleasance, and M Jones, in prep.). COSMIC mutation signature 5 was the most dominant mutation signature ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1); [Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1)), with 30.8% (95% interval 17.7%--43.4%) of somatic SNVs attributed to this signature. Signature 5 was also detected as a dominant signature in the majority of ICGC PanNETs indicating a common etiology of mutagenesis across PanNETs ([@MCS003814WILC39]). There were 15 somatic nonsynonymous mutations affecting protein-coding genes detected in the tumor biopsy, seven of which were subclonal ([Table 1](#MCS003814WILTB1){ref-type="table"}). Despite being recurrently mutated in PanNETs, we did not identify mutations affecting *DAXX*, *ATRX*, or *MEN1* in this G3 PanNET sample. Similarly, none of the five G3 PanNETs from the ICGC study harbored mutations in *DAXX*, *ATRX*, or *MEN1*.

###### 

Somatic nonsynonymous single-nucleotide variants (SNVs) and indels

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Gene        Chr   Position    Ref      Alt     HGVS codons         HGVS protein   Type        Genotype       Predicted Effect       dbSNP
  ----------- ----- ----------- -------- ------- ------------------- -------------- ----------- -------------- ------------------ -------------
  *HSPG2*     1     22149892    G        A       c.13093C\>T         p.Arg4365\*    SNV         Heterozygous   Stop gain               --

  *CNR2*      1     24202047    G        T       c.61C\>A            p.Pro21Thr     SNV         Heterozygous   Missense                --

  *DNAJC13*   3     132182654   A        T       c.1885A\>T          p.Thr629Ser    SNV         Heterozygous   Missense                --

  *MUC7*      4     71347240    T        C       c.779T\>C           p.Val260Ala    SNV         Subclonal      Missense            rs145745951

  *RAPGEF2*   4     160279276   A        C       c.4485A\>C          p.Gln1495His   SNV         Heterozygous   Missense                --

  *FRG1*      4     190876269   T        C       c.395T\>C           p.Ile132Thr    SNV         Subclonal      Missense            rs149113074

  *DPCR1*     6     30918448    T        C       c.2207T\>C          p.Phe736Ser    SNV         Subclonal      Missense                --

  *PTPN6*     12    7069329     C        T       c.1514C\>T          p.Ala505Val    SNV         Subclonal      Missense            rs185835888

  *AHNAK2*    14    105418798   T        C       c.2990A\>G          p.Lys997Arg    SNV         Subclonal      Missense            rs200638785

  *TXNDC2*    18    9887371     C        A       c.895C\>A           p.Leu299Ile    SNV         Subclonal      Missense            rs200059339

  *ZNF57*     19    2917901     A        G       c.1282A\>G          p.Thr428Ala    SNV         Subclonal      Missense                --

  *GRIK5*     19    42507823    C        T       c.2276G\>A          p.Arg759Gln    SNV         Heterozygous   Missense                --

  *SYNJ1*     21    34004062    A        G       c.3965T\>C          p.Ile1322Thr   SNV         Heterozygous   Missense                --

  *PLCXD1*    X     215957      C        CG      c.928dupG           p.Val310fs     Insertion   Heterozygous   Frameshift              --

  *USP7*      16    8989553     CTTCT\   CATAA   c.2858_2865delAT\   p.Gln954fs     Indel       Heterozygous   Frameshift         
                                TGAT             CAAGAAinsTTAT                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------

### Copy-Number Alterations {#s2b2}

The genome was subject to loss of one copy each of Chromosome 9 and 13 and broad deletions affecting Chromosomes 1, 2, and 6 ([Fig. 2](#MCS003814WILF2){ref-type="fig"}A). Combinatorial analysis of copy-number aberrations (CNAs) and SNVs did not identify loss of heterozygosity of any of the altered protein-coding genes. Homozygous deletion of *CDKN2A* and *CDKN2B* on Chromosome 9 and a single-copy loss of *RB1* were the main copy alterations of note. Comparison of *RB1* expression in this tumor sample with *RB1* expression across a compendium of all TCGA data sets as well as the average expression across all tissue types in the Illumina BodyMap reference RNA-seq data set was performed. Expression of *RB1* was in the 6th percentile compared to TCGA compendium and down-regulated 3.48-fold compared to the Illumina BodyMap, indicating low expression of *RB1* in this sample.

![Copy-number aberration and *TSC1--TMEM71* structural rearrangement in the G3 PanNET. (*A*) Circos plot illustrating copy-number alterations and loss of heterozygosity (LOH) observed in the tumor sample. (*B*) Genomic sequencing read alignment of the genomic regions affected by the rearrangement. Green reads that aligned to *TSC1* and purple reads that aligned to *TMEM71* indicate split reads that support the rearrangement. (*C*) Illustration of *TSC1--TMEM71* rearrangement generated by MAVIS ([@MCS003814WILC34]). The *TMEM71* and *TSC1* breakpoints are indicated at the chromosome, gene, and transcript level (B1 and B2, respectively, *upper* box). Protein-coding sequence associated with the respective transcripts are indicated by the black line and the amino acids included in the fusion product are indicated. Pfam (<http://pfam.xfam.org>) protein domains are indicated in the track below the transcript: Hamartin (PF04388). The predicted fusion transcript and protein-coding sequence are shown in the *lower* box (*TSC1* exons are colored green; *TMEM71* exons are colored blue).](MCS003814Wil_F2){#MCS003814WILF2}

### TSC1--TMEM71 Rearrangement {#s2b3}

Structural variants were identified using de novo assembly followed by variant detection. A novel somatic translocation between Chromosomes 8 and 9 (t(9;8)(q34.13;q24.22)) was detected in the genomic assembly ([Fig. 2](#MCS003814WILF2){ref-type="fig"}B) and supported by the transcriptomic assembly. The rearrangement resulted in an in-frame fusion of *TSC1* exons 1--8 (encoding amino acids 1--246) with *TMEM71* exons 8--10 (encoding amino acids 232--277) ([Fig. 2](#MCS003814WILF2){ref-type="fig"}C). *TSC1* encodes the tumor suppressor, hamartin. Hamartin heterodimerizes with the GTPase, tuberin, encoded by the *TSC2* gene. The TSC1/2 protein complex suppresses cell growth, largely by inhibiting the small G-protein Rheb, a crucial activator of the mTORC1 pathway ([@MCS003814WILC7]; [@MCS003814WILC18]). The predicted *TSC1--TMEM71* fusion protein identified in this tumor lacks protein sequence critical for *TSC2* binding and is thus predicted to disrupt TSC1 function ([@MCS003814WILC17]). Deletion of exon 9 alone has been shown to disrupt *TSC1--TSC2* dimer formation and downstream inhibition of mTORC1 kinase activity ([@MCS003814WILC36]), supporting this fusion as indeed a loss of function variant. Moreover, loss of heterozygosity as a result of whole Chromosome 9 loss is predicted to render the tumor deficient in *TSC1* activity ([Fig. 2](#MCS003814WILF2){ref-type="fig"}B). There is a significant reduction in the aligned RNA-seq read coverage of *TSC1* exons 9--23, downstream from the breakpoint, compared to upstream of the breakpoint, in support of the hypothesis that this tumor lacks a functional full-length copy of *TSC1* ([Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1)).

### CHD7--BEND2 Rearrangement {#s2b4}

A second novel somatic translocation between Chromosome 8 and the X chromosome was detected in the genomic assembly (t(8;X)(q12.2;p22.13)) ([Fig. 3](#MCS003814WILF3){ref-type="fig"}A), which was also supported by the transcriptomic assembly. The rearrangement results in a novel in-frame fusion between *CHD7* exons 1--2 (encoding amino acids 1--555) and *BEND2* exons 5--14 (encoding amino acids 165--800) ([Fig. 3](#MCS003814WILF3){ref-type="fig"}B). *CHD7* encodes the chromodomain helicase DNA-binding protein 7, a chromatin remodeling enzyme involved in differentiation and transcription regulation ([@MCS003814WILC40]; [@MCS003814WILC14]). Germline loss of function mutations or deletions of *CHD7* are found in patients with CHARGE syndrome, a disorder characterized by dysmorphic features and congenital anomalies in multiple organs. *CHD7* remodeling activity is required for neural crest cell gene expression networks, linking a lack of *CHD7* activity with CHARGE syndrome features ([@MCS003814WILC3]). The translocation observed in this G3 PanNET disrupts the majority of the protein-coding region of *CHD7*, resulting in loss of the chromodomains and helicase domain ([Fig. 3](#MCS003814WILF3){ref-type="fig"}B).

![*CHD7--BEND2* structural rearrangement and increased *BEND2* expression. (*A*) Genomic sequencing read alignment of the genomic regions affected by the rearrangement. Gold reads that aligned to *CHD7* and purple reads that aligned to *BEND2* indicate reads that support the rearrangement. (*B*) Illustration of *CHD7--BEND2* rearrangement. The *CHD7* and *BEND2* breakpoints are indicated at the chromosome, gene, and transcript level (B1 and B2, respectively, *upper* box). The protein-coding sequences associated with the respective transcripts are indicated by the black line, and the amino acids included in the fusion product are indicated. The predicted fusion transcript and protein-coding sequence are shown in the *lower* box (*CHD7* exons are colored blue; *BEND2* exons are colored green). Pfam protein domains are indicated by the tracks below the transcript: SNF2_N (F00176), helicase_C (PF00271), Chromo (PF00385), BRK (PF07533), BEN (PF10523). (*C*) Genomic sequencing reads (*top*) and RNA sequencing reads (*bottom*) aligned to the *BEND2* gene. Genomic reads that are affected by the rearrangement are colored purple. The *BEND2* fusion breakpoint is indicated by the dashed line. RNA-seq coverage downstream from the breakpoint (exons 5--14) is increased compared to upstream of the breakpoint (exons 1--4). (*D*) Boxplot of *BEND2* RPKM (log~10~ transformed) across a panel of 40 TCGA data sets. *BEND2* log~10~(RPKM) for this patient sample is indicated by the red horizontal line.](MCS003814Wil_F3){#MCS003814WILF3}

The *CHD7* fusion partner *BEND2* encodes BEN domain-containing 2, a relatively uncharacterized protein. Alignment of RNA-seq reads across the *BEND2* genomic loci revealed an increase in expression of *BEND2* downstream from the breakpoints, indicating the fusion of *BEND2* with *CHD7* enhances transcription of *BEND2* ([Fig. 3](#MCS003814WILF3){ref-type="fig"}C). Furthermore, *BEND2* was found to be an extreme high expression outlier in this tumor compared to all TCGA disease types ([Fig. 3](#MCS003814WILF3){ref-type="fig"}D). BEND2 protein is solely characterized by the presence of two BEN domains, which have been demonstrated to bind DNA and are typically found in proteins involved in transcription and chromatin regulation ([@MCS003814WILC1]; [@MCS003814WILC37]; [@MCS003814WILC9], [@MCS003814WILC10]). Interestingly, a fusion between *EWSR1* amino-terminal transactivation domain and *BEND2* was identified in two patients in the ICGC study, one of which was a grade 3 PanNET ([@MCS003814WILC39]). Moreover, the *EWSR1--BEND2* rearrangement also similarly resulted in a fusion transcript containing exons 9--14 of *BEND2*, indicating a common breakpoint among these *BEND2* rearrangements. In addition, a recurring fusion between *MN1* and *BEND2* was identified in three patients with central nervous system primitive neuroectodermal tumors ([@MCS003814WILC43]). This rearrangement also resulted in the juxtaposition of a transactivation domain donated by *MN1* with *BEND2*. The cumulative evidence leads to the hypothesis that activation of BEND2, either by fusion with a transactivation domain or potentially by increased expression, may promote oncogenic activity.

### Gene Expression Analysis {#s2b5}

RNA-seq data were compiled as gene-specific RPKM values for all seven PanNEN samples (six PanNETs and one PanNEC) sequenced as part of the POG initiative. As these samples represented several different tumor grades (two grade 1, three grade 2, and two grade 3), we evaluated the impact of tumor grade on gene expression. A mixed-effects model fit to the principal components showed that tumor grade accounted for 5% of the variability in the transcriptomic data. Based on this observation, elastic net regression was used to identify genes that could characterize tumor grade in these samples ([Supplemental Fig. S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1)). This approach revealed genes associated with PanNEN grade. Along with the *MKI67*, which encodes Ki-67, high expression of *RIPPLY3*, *CIT*, *YBX2*, and *KIF19* was also associated with the G3 PanNEN signature. *RIPPLY3* is expressed in islet β cells of the pancreas and may play a role in regulating proliferation and differentiation of β cells ([@MCS003814WILC31]). Last, hierarchical clustering of the samples based on highly variable genes revealed that tumors with similar grade did not cluster together ([Supplemental Fig. S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1)). These experiments suggested that tumor grade did not significantly bias global gene expression in these samples, but revealed potential gene signatures associated with tumor grade that merit further study.

Somatostatin receptors (SSTRs) are targeted by the peptide hormone somatostatin, eliciting an antiproliferative effect ([@MCS003814WILC15]; [@MCS003814WILC35]; [@MCS003814WILC6]). Somatostatin analogs (SSAs), such as octreotide, have played a role in the clinical setting for both tumor localization and therapeutic intervention. Given the clinical relevance of SSTRs, we investigated the expression of SSTR-encoding genes in this patient sample. There are five *SSTR* genes in the human genome that have been demonstrated to be heterogeneously expressed across gastro-entero-pancreatic neuroendocrine tumors ([@MCS003814WILC21]; [@MCS003814WILC32]). To assess the relative *SSTR* expression in this patient sample, RNA expression of *SSTR1--5* was compared among this patient sample and six additional metastatic PanNENs ([@MCS003814WILC45]). In agreement with a previous report ([@MCS003814WILC32]), *SSTR1* and *SSTR2* were most frequently expressed across the cohort followed by *SSTR3* and *SSTR5* ([Supplemental Fig. S5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1)). Normalized *SSTR* gene expression was consistently found to be low in this patient sample compared to other PanNEN samples. This observation is in line with SSA scintillation imaging, which was negative for this patient, providing a rationale for not pursuing SSA-based therapy ([Fig. 4](#MCS003814WILF4){ref-type="fig"}).

![Low expression of SSTR genes in the G3 PanNET. *SSTR1*, *SSTR2*, *SSTR3*, and *SSTR5* RPKM normalized to the mean of the cohort were plotted for seven metastatic PanNET samples. Relative SSTR gene expression for this patient sample is highlighted in red.](MCS003814Wil_F4){#MCS003814WILF4}

DISCUSSION {#s3}
==========

Single-Nucleotide and Copy-Number Variants {#s3a}
------------------------------------------

Here, we describe the molecular characterization of a patient with the recently recognized distinct class of PanNEN, PanNET G3. Similar to other reports that have investigated the PanNET genomic landscape across the broad spectrum of classifications, the mutational burden of this PanNET G3 sample was relatively low compared to pancreatic ductal adenocarcinoma. Only 15 nonsynonymous SNVs and indels were identified, many of which were subclonal. Despite a high rate of occurrence in PanNETs ([@MCS003814WILC20]; [@MCS003814WILC46]; [@MCS003814WILC39]), mutations or copy losses were not identified in *DAXX*, *ATRX*, or *MEN1*. High-grade poorly differentiated PanNECs were found to have recurrent *RB1* mutations and reduced protein expression, a characteristic not frequently observed in G1 and G2 PanNETs ([@MCS003814WILC46]; [@MCS003814WILC4]). A single-copy loss and low expression of *RB1* and homozygous loss of the upstream cell cycle--negative regulators *CDKN2A* and *CDKN2B*, which have also been observed to be mutated in a subset of PanNECs ([@MCS003814WILC4]), may also contribute to the high-grade nature of this G3 PanNET.

Structural Rearrangements {#s3b}
-------------------------

Loss-of-function mutations in *TSC1* and *TSC2* occur in a subset of PanNETs ([@MCS003814WILC20]; [@MCS003814WILC39]). Moreover, patients with the hereditary disorder tuberous sclerosis have an increased incidence of low-grade, well-differentiated PanNETs, further supporting a role for these tumor suppressors in PanNET oncogenesis ([@MCS003814WILC26]). Mutations in other components of the PI3K/mTOR signaling pathway including *PTEN*, *DEPDC5*, and *PIK3CA* have also been observed ([@MCS003814WILC20]; [@MCS003814WILC46]; [@MCS003814WILC45]). A novel somatic structural variant disrupting the *TSC1* gene was identified in this tumor sample. The structural variant resulted in an in-frame fusion with the transmembrane protein-encoding gene, *TMEM71*, resulting in loss of key residues required for TSC1/2 protein complex formation. Gene fusions are more typically associated with oncogene activation as opposed to loss of function of tumor suppressors, rendering this a relatively uncommon mechanism of gene inactivation.

The mTOR inhibitor, everolimus, has been shown to significantly increase progression-free survival in phase II and III trials and is approved for use in the PanNET setting ([@MCS003814WILC47], [@MCS003814WILC48], [@MCS003814WILC49], [@MCS003814WILC50]). Given the incidence of mTOR pathway alterations in PanNETs, there is further rationale for treatment of patients predicted to have an aberrant mTOR pathway with mTOR inhibitors. Continued investigation will be required to determine if *TSC1*/*TSC2*-deficient PanNETs have a differential response to mTOR inhibitors compared to the other PanNETs and how this impacts response to everolimus in grade 3 well-differentiated PanNETs, which were not included in RADIANT 3 ([@MCS003814WILC49]). The majority of reported inactivating *TSC1/2* variants detected in PanNETs are SNVs or indels. The aberrant *TSC1* fusion identified in this tumor highlights a potentially underappreciated mechanism of tumor-suppressor inactivation by structural rearrangement. Incorporation of structural variant detection for tumor suppressors including *TSC1* and other genes associated with potentially actionable pathways may further increase the proportion of patients that could benefit from targeted therapies.

A novel rearrangement between *CHD7* and *BEND2* disrupting the majority of *CHD7* and driving expression of *BEND2* was identified in this patient sample. It is unclear what the biological impact of such a fusion would have on the tumor, if any; however, recurrent fusions affecting *BEND2* in this disease type indicate it may contribute to tumor biology ([@MCS003814WILC39]). Although the function of the BEND2 protein has not been studied, the presence of two BEN domains suggests it may play a role in chromatin regulation and gene expression. Studies of other proteins that encode BEN domains have revealed a direct and motif-specific interaction of the BEN domain with DNA ([@MCS003814WILC9], [@MCS003814WILC10]). Furthermore, another BEN domain--containing protein, BEND3, specifically binds heterochromatin and is proposed to contribute to transcriptional repression ([@MCS003814WILC37]). Another homolog, BEND5, has been shown to similarly specifically localize to neural cortex and also stimulate transcription repression ([@MCS003814WILC9]). Further investigation into the function of BEND2 will be required to assess the relevance of *BEND2* rearrangements found in a subset of PanNETs.

SSTR Expression {#s3c}
---------------

SSA tumor localization was negative in this patient, indicating a lack of SSTR expression on tumor cells. In agreement with the pathology assessment, gene expression analysis of the five SSTR genes revealed low expression compared to a panel of previously reported metastatic PanNETs ([@MCS003814WILC45]). Given the application of SSAs in the therapeutic setting, reduced SSTR expression as determined by lack of SSA imaging and gene expression analysis may indicate inherent resistance to SSA-based treatment.

CONCLUSION {#s4}
==========

This report represents the complete genomic and transcriptomic description of a well-differentiated grade 3 PanNET, which to date has had limited molecular characterization. Whole-genome sequencing revealed a lack of variants in the frequently mutated genes *ATRX*, *DAXX*, and *MEN1* and identified novel structural rearrangements. Discrimination of this class of tumor in future studies will be critical for understanding the molecular mechanisms that drive their phenotypic distinction.

METHODS {#s5}
=======

Sample Collection and Processing {#s5a}
--------------------------------

Following informed consent, patients underwent image-guided metastatic biopsies as part of the POG program of British Columbia (NCT02155621). Eight core biopsies using 18-22G biopsy needles were embedded in optimal cutting temperature (OCT) compound for subsequent sectioning and sequencing library preparation. Tumor sections were reviewed by a pathologist to confirm the diagnosis, evaluate tumor content and cellularity, and select areas most suitable for DNA and RNA extraction. Peripheral venous blood samples were obtained at the time of biopsy and leukocytes isolated for use as a germline reference. DNA and RNA were extracted for genomic and transcriptomic library construction, which have been previously described in detail ([@MCS003814WILC23]).

Sequencing and Bioinformatics {#s5b}
-----------------------------

Paired-end reads were generated on an Illumina HiSeq2500 sequencer and aligned to the human reference genome (GSCh37; available from <http://www.bcgsc.ca/downloads/genomes/9606/hg19/1000genomes/bwa_ind/genome>) by the BWA aligner (v0.7.6) ([@MCS003814WILC28]). Sequencing read lengths were 125 bp. Somatic single-nucleotide variants (SNVs) and small insertions/deletions were processed using SAMtools ([@MCS003814WILC29]), MutationSeq (v4.3.5) ([@MCS003814WILC12]), Strelka (v1.0.6) ([@MCS003814WILC38]), and Trans-ABySS (v1.4.10) ([@MCS003814WILC42]). Regions of CNA were determined using CNAseq (v0.0.8) ([@MCS003814WILC22]) and LOH by APOLLOH (v0.1.2) ([@MCS003814WILC16]). Tumor content and ploidy models were estimated from sequencing data through analysis of the CNA ratios and allelic frequencies of each chromosome. This was then compared to in-house theoretical models for different ploidy at various tumor contents. Tumor content and sequencing coverage were as shown in [Table 2](#MCS003814WILTB2){ref-type="table"}.

###### 

Sequencing coverage table

  Library ID                RNA/DNA                 Aligned Reads   Coverage
  ------------------------- ----------------------- --------------- ----------
  P02594 (Matched Normal)   DNA (PCR-free WGS)      993322416       37×
  P02600 (Tumor)            DNA (PCR-free WGS)      2386018119      94×
  P02603 (Tumor)            RNA (strand-specific)   371042140       

Structural variants were detected by de novo assembly of tumor reads using ABySS (v1.3.4) ([@MCS003814WILC5]) and Trans-ABySS ([@MCS003814WILC036]), followed by variant discovery using DELLY (v0.7.3) ([@MCS003814WILC33]). Structural variants were visualized using MAVIS ([@MCS003814WILC34]). Genomic and transcriptomic sequencing read alignments were visualized using Integrative Genomics Viewer (<http://software.broadinstitute.org/software/igv/>). Reads were colored by insert size and chromosome of the paired read to reveal reads that supported the structural rearrangements.

Mutation Signature Analysis {#s5c}
---------------------------

The mutation signature profile was determined by classifying genomic SNVs into 96 classes based on variant and 3′/5′ mutation context to obtain a mutation catalog vector as described by [@MCS003814WILC2]. To determine the best fit to a consensus set of 30 mutation signatures (available at <http://cancer.sanger.ac.uk/cosmic/signatures>), we used Markov chain Monte Carlo (MCMC) to determine the full Bayesian solution posterior of the exposure vector **e** in the multinomial mixture model **m** = **Se** using the signIT package (<https://github.com/eyzhao/SignIT/>) ([@MCS003814WILC51]). **S** is a known 96 × 30 matrix of consensus signatures, **m** is the 96-element mutation catalog, and the members of **e** denote each signature\'s relative contribution to the overall mutation burden. The MCMC posterior sample was examined to model the variance inherent to **m**, the distributions of which are shown in [Supplemental Figure S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003814/-/DC1). Where confidence intervals are reported in the text, 95% simulated interval was reported using the 2.5 percentile and 97.5 percentile values for each signature exposure. This allows estimation of statistical confidence, with the caveat that it relies upon the underlying assumption that the 30-signature reference set accurately reflects the space of possible signatures.

Gene Expression Analysis {#s5d}
------------------------

RNA-seq reads were processed as previously described in [@MCS003814WILC41]. Gene expression was determined as the number of reads per kilobase of transcript per million mapped reads (RPKM). For *SSTR* gene expression analysis, *SSTR1-5* RPKM was compared across a cohort of seven PanNENs that were sequenced as part of the POG project ([@MCS003814WILC45]). Normalized *SSTR1*, *SSTR2*, *SSTR3*, and *SSTR5* expression was calculated by dividing RPKM by the mean RPKM for the cohort. For pan-TCGA *BEND2* expression comparison, log~10~ transformed *BEND2* RPKM from TCGA-sequenced tumor samples representing 40 disease and disease subtype data sets was plotted as a boxplot. *BEND2* RPKM, as determined using the GAF 2.0 gene model (geneontology.org), was plotted as a red horizontal line.

The effect of tumor grade on the transcriptome was evaluated using the PVCA package in R (<http://bioconductor.org/packages/release/bioc/html/pvca.html>). Expression signatures for tumor grade were determined using elastic net regression. An elastic net model was fit to the whole transcriptome data, with the predictive outcome being tumor grade. Highly predictive features were quantified using weight analysis of the fitted model and clustered using Euclidean distance and complete hierarchical clustering.

Clustering based on gene expression (RPKM) was performed on the top 1% variable genes selected from seven PanNENs of varying grade that were sequenced as part of the POG initiative and plotted as a heatmap. Rows (genes) and columns (samples) were clustered using the average and Manhattan methods, respectively. Tumor histology, Ki-67 staining percentage, grade, sex, and tumor content as determined by bioinformatics analysis (biofx_tc) were indicated in the horizontal tracks.
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The whole-genome sequencing and RNA-seq data for this case are available as .bam files from the European Genome-phenome Archive (EGA; [www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) as part of the study EGAS00001001159, accession ID EGAD00001004715. The *TSC1*-disrupting and *CHD7--BEND2* gene fusions were submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000897763 and SCV000897764, respectively.
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